Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 3/20 | 0.43 |
| ▸ | CCR5 known ✓ | P51681 | 2/20 | 0.43 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.43 |
| ▸ | HSP90AB1 known ✓ | P08238 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3710107 | 1.00 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| Hydrochloric Acid SCHEMBL3704751 | 1.00 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL8194 | 0.96 | ALDH1A1 (0.67) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL30099834 | 0.96 | ALDH1A1 (0.67) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL28519048 | 0.93 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| Hydrogen Sulfide SCHEMBL29184282 | 0.93 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL29592061 | 0.93 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL29095245 | 0.93 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| Water SCHEMBL28824188 | 0.93 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 | |
| SCHEMBL27860715 | 0.93 | ALDH1A1 (0.63) | ALDH1A1MAPTKDM4EPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3177619-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-14 | — | — | EP | claimed |
| CN-106795156-A | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2017-05-31 | — | — | CN | claimed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | claimed |
| WO-2009111031-A2 | METHODS OF TREATING VASOMOTOR SYMPTOMS | INTRA-CELLULAR THERAPIES, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-5726197-A | ADRENORECEPTORS AND ADMINISTERING | SYNTEX (U.S.A.) INC. (US) | 1998-03-10 | — | — | US | claimed |
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246018-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-05 | — | — | WO | disclosed |
| CN-118203585-A | Pharmaceutical use of ENPP1 inhibitors | 上海翊石医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-116262750-A | Aromatic heterocyclic compound and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-116114873-A | Use of fasted mimicking dietary packages | 南加利福尼亚大学 | 2023-05-16 | — | — | CN | disclosed |
| EP-4077306-A1 | COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-110204544-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-102741249-A | Hetaryl-[1,8]naphthyridine derivatives | MERCK PATENT GMBH | 2012-10-17 | — | — | CN | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
| EP-2161998-A1 | NOVEL METHODS | Intra-Cellular Therapies, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009111031-A2 | METHODS OF TREATING VASOMOTOR SYMPTOMS | INTRA-CELLULAR THERAPIES, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2008150528-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-12-11 | — | — | WO | disclosed |
| CN-1289501-C | Fused heterotricyclic compound, process for preparing compounds and drugs containing the same | EISAI CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| CN-1409713-A | Tricyclic fused heterocyclic compound, process for producing the same, and pharmaceutical comprising the same | EISAI CO LTD (JP) | 2003-04-09 | — | — | CN | disclosed |
| EP-0364254-A2 | Decahydro-8H-isoquino[2,1-g][1,6]naphthyridine derivatives and related compounds | SYNTEX (U.S.A.) INC. (US) | 1990-04-18 | — | — | EP | disclosed |